Claims for Patent: 7,304,122

Summary for Patent: 7,304,122

Title:	Elastomeric functional biodegradable copolyester amides and copolyester urethanes
Abstract:	The present invention provides elastomeric copolyester amides, elastomeric copolyester urethanes, and methods for making the same. The polymers that are based on .alpha.-amino acids and possess suitable physical, chemical and biodegradation properties. The polymers are useful as carriers of drugs or other bioactive substances. The polymers can be linked, intermixed, or a combination thereof, to one or more drugs.
Inventor(s):	Chu; Chih-Chang (Ithaca, NY), Katsarava; Ramaz (Tbilisi, GE)
Assignee:	Cornell Research Foundation, Inc. (Ithaca, NY)
Application Number:	10/362,848
Patent Claims:	1. A polymer of formula (VII) ##STR00030## wherein m is about 0.1 to about 0.9; p is about 0.9 to about 0.1; n is about 50 to about 150; each R.sup.1 is independently (C.sub.2-C.sub.20)alkyl; each R.sup.2 is independently hydrogen, or (C.sub.6-C.sub.10)aryl(C.sub.1-C.sub.6)alkyl; each R.sup.3 is independently hydrogen, (C.sub.1-C.sub.6)alkyl, (C.sub.2-C.sub.6)alkenyl, (C.sub.2-C.sub.6)alkynyl, or (C.sub.6-C.sub.10)aryl(C.sub.1-C.sub.6)alkyl; and each R.sup.4 is independently (C.sub.2-C.sub.20)alkyl; that is linked to one or more drugs. 2. The polymer of claim 1 wherein a residue of the polymer is linked directly to a residue of the drug. 3. The polymer of claim 2 wherein the residue of the polymer is linked directly to the residue of the drug through an amide, ester, ether, amino, ketone, thioether, sulfinyl, sulfonyl, disulfide, or a direct linkage. 4. The polymer of claim 2 wherein the residue of the polymer is linked directly to the residue of the drug through one of the following linkages: --N(R)C(.dbd.O)--, --C(.dbd.O)N(R)--, --OC(.dbd.O)--, --C(.dbd.O)O--, --O--, --C(.dbd.O)--, --S--, --S(O)--, --S(O).sub.2--, --S--S--, --N(R)--, or C--C; wherein each R is independently H or (C.sub.1-C.sub.6)alkyl. 5. The polymer of claim 1 wherein a residue of the polymer is linked to a residue of the drug, through a linker. 6. The polymer of claim 5 wherein the linker separates the residue of the polymer and the residue of the drug by about 5 angstroms to about 200 angstroms, inclusive, in length. 7. The polymer of claim 5 wherein (1) the residue of the polymer is linked to the linker and (2) the linker is linked to the residue of the drug, independently, through an amide, ester, ether, amino, ketone, thioether, sulfinyl, sulfonyl, disulfide, or a direct linkage. 8. The polymer of claim 5 wherein (1) the residue of the polymer is linked to the linker and (2) the linker is linked to the residue of the drug, independently, through one of the following linkages: --N(R)C(.dbd.O)--, --C(.dbd.O)N(R)--, --OC(.dbd.O)--, --C(.dbd.O)O--, --O--, --C(.dbd.O)--, --S--, --S(O)--, --S(O).sub.2--, --S--S--, --N(R)--, or C--C; wherein each R is independently H or (C.sub.1-C.sub.6)alkyl. 9. The polymer of claim 5 wherein the linker is a divalent radical of the formula W-A-Q wherein A is (C.sub.1-C.sub.24)alkyl, (C.sub.2-C.sub.24)alkenyl, (C.sub.2-C.sub.24)alkynyl, (C.sub.3-C.sub.8)cycloalkyl, or (C.sub.6-C.sub.10) aryl, wherein W and Q are each independently --N(R)C(.dbd.O)--, --C(.dbd.O)N(R)--, --OC(.dbd.O)--, --C(.dbd.O)O--, --O--, --S--, --S(O)--, --S(O).sub.2--, --S--S--, --N(R)--, --C(.dbd.O)--, or a direct bond; wherein each R is independently H or (C.sub.1-C.sub.6)alkyl. 10. The polymer of claim 5 wherein the linker is an .alpha..omega.-divalent radical formed from a peptide or an amino acid. 11. The polymer of claim 10 wherein the peptide comprises 2 to about 25 amino acids. 12. The polymer of claim 10 wherein the peptide is poly-L-lysine, poly-L-glutamic acid, poly-L-aspartic acid, poly-L-histidine, poly-L-ornithine, poly-L-serine, poly-L-threonine, poly-L-tyrosine, poly-L-leucine, poly-L-lysine-L-phenylalanine, poly-L-arginine, or poly-L-lysine-L-tyrosine. 13. The polymer of claim 1 wherein the one or more drugs are each independently: a polynucleotide, polypeptide, oligonucleotide, gene therapy agent, nucleotide analog, nucleoside analog, polynucleic acid decoy, therapeutic antibody, abciximab, anti-inflammatory agent, blood modifier, anti-platelet agent, anti-coagulation agent, immune suppressive agent, anti-neoplastic agent, anti-cancer agent, anti-cell proliferation agent, or nitric oxide releasing agent. 14. A formulation comprising a polymer of formula (VII) ##STR00031## wherein m is about 0.1 to about 0.9; p is about 0.9 to about 0.1; n is about 50 to about 150; each R.sup.1 is independently (C.sub.2-C.sub.20)alkyl; each R.sup.2 is independently hydrogen, or (C.sub.6-C.sub.10)aryl(C.sub.1-C.sub.6)alkyl; each R.sup.3 is independently hydrogen, (C.sub.1-C.sub.6)alkyl, (C.sub.2-C.sub.6)alkenyl, (C.sub.2-C.sub.6)alkynyl, or (C.sub.6-C.sub.10)aryl(C.sub.1-C.sub.6)alkyl; and each R.sub.4 is independently (C.sub.2C.sub.20)alkyl; and one or more drugs. 15. The formulation of claim 14 wherein the one or more drugs are each independently: a polynucleotide, polypeptide, oligonucleotide, gene therapy agent, nucleotide analog, nucleoside analog, polynucleic acid decoy, therapeutic antibody, abciximab, anti-inflammatory agent, blood modifier, anti-platelet agent, anti-coagulation agent, immune suppressive agent, anti-neoplastic agent, anti-cancer agent, anti-cell proliferation agent, or nitric oxide releasing agent. 16. A polymer of formula (XI) ##STR00032## wherein m is about 0.1 to about 0.9; p is about 0.9 to about 0.1; n is about 50 to about 150; each R.sup.2 is independently hydrogen, or (C.sub.6-C.sub.10)aryl(C.sub.1-C.sub.6)alkyl; each R.sup.3 is independently hydrogen, (C.sub.1-C.sub.6)alkyl, (C.sub.2-C.sub.6)alkenyl, (C.sub.2-C.sub.6)alkynyl, or (C.sub.6-C.sub.10)aryl(C.sub.1-C.sub.6)alkyl; each R.sup.4 is independently (C.sub.2-C.sub.20)alkyl; and each R.sup.6 is independently (C.sub.2-C.sub.20)alkyl or (C.sub.2-C.sub.8)alkyloxy(C.sub.2-C.sub.20)alkyl; that is linked to one or more drugs. 17. The polymer of claim 16 wherein a residue of the polymer is linked directly to a residue of the drug. 18. The polymer of claim 17 wherein the residue of the polymer is linked directly to the residue of the drug through an amide, ester, ether, amino, ketone, thioether, sulfinyl, sulfonyl, disulfide, or a direct linkage. 19. The polymer of claim 16 wherein the residue of the polymer is linked directly to the residue of the drug through one of the following linkages: --N(R)C(.dbd.O)--, --C(.dbd.O)N(R)--, --OC(.dbd.O)--, --C(.dbd.O)O--, --O--, --C(.dbd.O)--, --S--, --S(O)--, --S(O).sub.2--, --S--S--, --N(R)--, or C--C; wherein each R is independently H or (C.sub.1-C.sub.6)alkyl. 20. The polymer of claim 16 wherein a residue of the polymer is linked to a residue of the drug, through a linker. 21. The polymer of claim 20 wherein the linker separates the residue of the polymer and the residue of the drug by about 5 angstroms to about 200 angstroms, inclusive, in length. 22. The polymer of claim 20 wherein (1) the residue of the polymer is linked to the linker and (2) the linker is linked to the residue of the drug, independently, through an amide, ester, ether, amino, ketone, thioether, sulfinyl, sulfonyl, disulfide, or a direct linkage. 23. The polymer of claim 20 wherein (1) the residue of the polymer is linked to the linker and (2) the linker is linked to the residue of the drug, independently, through one of the following linkages: --N(R)C(.dbd.O)--, --C(.dbd.O)N(R)--, --OC(.dbd.O)--, --C(.dbd.O)O--, --O--, --C(.dbd.O)--, --S--, --S(O)--, --S(O).sub.2--, --S--S--, --N(R)--, or C--C; wherein each R is independently H or (C.sub.1-C.sub.6)alkyl. 24. The polymer of claim 20 wherein the linker is a divalent radical of the formula W-A-Q wherein A is (C.sub.1-C.sub.24)alkyl, (C.sub.2-C.sub.24)alkenyl, (C.sub.2-C.sub.24)alkynyl, (C.sub.3-C.sub.8)cycloalkyl, or (C.sub.6-C.sub.10)aryl, wherein W and Q are each independently --N(R)C(.dbd.O)--, --C(.dbd.O)N(R)--, --OC(.dbd.O)--, --C(.dbd.O)O--, --O--, --S--, --S(O)--, --S(O).sub.2--, --S--S--, --N(R)--, --C(.dbd.O)--, or a direct bond; wherein each R is independently H or (C.sub.1-C.sub.6)alkyl. 25. The polymer of claim 20 wherein the linker is a 1, 107 -divalent radical formed from a peptide or an amino acid. 26. The polymer of claim 25 wherein the peptide comprises 2 to about 25 amino acids. 27. The polymer of claim 25 wherein the peptide is poly-L-lysine, poly-L-glutamic acid, poly-L-aspartic acid, poly-L-histidine, poly-L-ornithine, poly-L-serine, poly-L-threonine, poly-L-tyrosine, poly-L-leucine, poly-L-lysine-L-phenylalanine, poly-L-arginine, or poly-L-lysine-L-tyrosine. 28. The polymer of claim 16 wherein the one or more drugs are each independently: a polynucleotide, polypeptide, oligonucleotide, gene therapy agent, nucleotide analog, nucleoside analog, polynucleic acid decoy, therapeutic antibody, abciximab, anti-inflammatory agent, blood modifier, anti-platelet agent, anti-coagulation agent, immune suppressive agent, anti-neoplastic agent, anti-cancer agent, anti-cell proliferation agent, or nitric oxide releasing agent. 29. A formulation comprising a polymer of formula (XI) ##STR00033## wherein m is about 0.1 to about 0.9; p is about 0.9 to about 0.1; n is about 50 to about 150; each R.sup.2 is independently hydrogen, or (C.sub.6-C.sub.10)aryl(C.sub.1-C.sub.6)alkyl; each R.sub.3 is independently hydrogen, (C.sub.1-C.sub.6)alkyl, (C.sub.2-C.sub.6)alkenyl, (C.sub.2-C.sub.6)alkynyl, or (C.sub.6-C.sub.10)aryl(C.sub.1-C.sub.6)alkyl; each R.sup.4 is independently (C.sub.2-C.sub.20)alkyl; and each R.sup.6 is independently (C.sub.2-C.sub.20)alkyl or (C.sub.2-C.sub.8)alkyloxy(C.sub.2-C.sub.20)alkyl; and one or more drugs. 30. The formulation of claim 29 wherein the one or more drugs are each independently: a polynucleotide, polypeptide, oligonucleotide, gene therapy agent, nucleotide analog, nucleoside analog, polynucleic acid decoy, therapeutic antibody, abciximab, anti-inflammatory agent, blood modifier, anti-platelet agent, anti-coagulation agent, immune suppressive agent, anti-neoplastic agent, anti-cancer agent, anti-cell proliferation agent, or nitric oxide releasing agent. 31. The polymer of claim 1 wherein each R.sup.1 is independently (CH.sub.2).sub.4, (CH.sub.2).sub.8, or (CH.sub.2).sub.12. 32. The polymer of claim 1 wherein each R.sup.2 is independently hydrogen or benzyl. 33. The polymer of claim 1 wherein each R.sup.3 is independently iso-butyl or benzyl. 34. The polymer of claim 1 wherein each R.sup.4 is independently (CH.sub.2).sub.4, (CH.sub.2).sub.6, (CH.sub.2).sub.8, or (CH.sub.2).sub.12. 35. The polymer of claim 1 wherein p/(p+m) is about 0.9 to about 0.1. 36. The polymer of claim 1 wherein m/(p+m) is about 0.1 to about 0.9. 37. The polymer of claim 16 wherein each R.sup.2 is independently hydrogen or benzyl. 38. The polymer of claim 16 wherein each R.sup.3 is independently iso-butyl or benzyl. 39. The polymer of claim 16 wherein each R.sup.4 is independently (CH.sub.2).sub.4, (CH.sub.2).sub.6, (CH.sub.2).sub.8, or (CH.sub.2).sub.12. 40. The polymer of claim 16 wherein each R.sup.6 is independently (CH.sub.2).sub.3 or (CH.sub.2).sub.2--O--(CH.sub.2).sub.2. 41. The polymer of claim 16 wherein p/(p+m) is about 0.9 to about 0.1. 42. The polymer of claim 16 wherein m/(p+m) is about 0.1 to about 0.9. 43. The formulation of claim 14 wherein each R.sup.1 is independently (CH.sub.2).sub.4, (CH.sub.2).sub.8, or (CH.sub.2).sub.12. 44. The formulation of claim 14 wherein each R.sup.2 is independently hydrogen or benzyl. 45. The formulation of claim 14 wherein each R.sup.3 is independently iso-butyl or benzyl. 46. The formulation of claim 14 wherein each R.sup.4 is independently (CH.sub.2).sub.4, (CH.sub.2).sub.6, (CH.sub.2).sub.8, or (CH.sub.2).sub.12. 47. The formulation of claim 14 wherein p/(p+m) is about 0.9 to about 0.1. 48. The formulation of claim 14 wherein m/(p+m) is about 0.1 to about 0.9. 49. The formulation of claim 29 wherein each R.sup.2 is independently hydrogen or benzyl. 50. The formulation of claim 29 wherein each R.sup.3 is independently iso-butyl or benzyl. 51. The formulation of claim 29 wherein each R.sup.4 is independently (CH.sub.2).sub.4, (CH.sub.2).sub.6, (CH.sub.2).sub.8, or (CH.sub.2).sub.12. 52. The formulation of claim 29 wherein each R.sup.6 is independently (CH.sub.2).sub.3 or (CH.sub.2).sub.2--O--(CH.sub.2).sub.2. 53. The formulation of claim 29 wherein p/(p+m) is about 0.9 to about 0.1. 54. The formulation of claim 29 wherein m/(p+m) is about 0.1 to about 0.9.

Details for Patent 7,304,122

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REOPRO	abciximab	Injection	103575	12/22/1994		2039-02-26